TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Participants will be randomized to receive either quetiapine or trazodone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Participants will be randomized to receive either quetiapine or trazodone.
Study: NCT04827589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study: NCT05758987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)
Description: A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure
Description: A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
Study: NCT05124288

Intervention type: OTHER
Intervention: Observations on Relapsed AML Allogeneic Transplanted patients
Description: This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
Study: NCT04965753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-609
Description: FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.
Study: NCT06371469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHeBAC
Description: Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
Study: NCT05266924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen
Description: fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen
Description: fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
Study: NCT06371469

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
Study: NCT06239805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QMR
Description: A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off.
Study: NCT06232395

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA test
Description: circulating DNA test

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA test
Description: circulating DNA test
Study: NCT04696653

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Unit Based Safety Program (CUSP)
Description: CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
Study: NCT04707365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor samples
Description: for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
Study: NCT04685928

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI and MRI-guided prostate biopsy
Description: Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TP-arm Systematic biopsy
Description: Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
Study: NCT04766099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childbirth Educational Video
Description: Educational video describing techniques for pushing
Study: NCT05412966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-002B
Description: PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSET-O
Description: reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
Study: NCT05929248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 160mg once a week for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used once a week in combination with standard treatment
Study: NCT06300944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: A maintenance dose of saline is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondansetron 16mg, diluted with appropriate normal saline, a total of 100ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: A maintenance dose of esketamine is 0.2mg/kg/h and postoperative PCIA regimen was Sufentanil 2ug/kg, ondanseetron 16mg, esketamine 0.75mg/kg, diluted with appropriate normal saline, a total of 100ml
Study: NCT06224036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDB0131
Description: JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDB0131
Description: JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDB0131
Description: JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delamanid
Description: Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethylpyrazine rifampicide (II)
Description: Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
Study: NCT05998460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose-Guided Eating with CGM
Description: The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGM only
Description: Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM only
Description: Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
Study: NCT04629443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 64315 (also referred as MIK665) and azacitidine
Description: The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days.
Study: NCT05817214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
Study: NCT05105399

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus plane block (continuous or single-shot)
Description: Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus plane block (continuous or single-shot)
Description: Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
Study: NCT06511115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits.
Study: NCT04295213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oligosaccharides
Description: 1 dose a day of oligosaccharides or placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oligosaccharides
Description: 1 dose a day of oligosaccharides or placebo
Study: NCT04918407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin
Study: NCT06210386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: noninvasive ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: noninvasive ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: noninvasive ventilation
Study: NCT05062720

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local consolidative therapy
Description: Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
Study: NCT05148702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic - standard duration
Description: Clinician decided antibiotic and duration of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic - fixed-extended-duration
Description: Clinician decided antibiotic for a fixed duration of 28 days.
Study: NCT05897983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado exercises plus TENS device
Description: Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado exercises plus TENS device
Description: Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabado exercises plus TENS device
Description: Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
Study: NCT05663164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B
Description: vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT05865171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablets for oral administration.
Study: NCT05105568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process-based therapy
Description: Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
Study: NCT04472845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1 week RT
Description: RT will be delivered over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 2 week RT
Description: RT will be delivered over 2 week
Study: NCT06001866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval-based verb learning
Description: Learning sessions: Novel verbs are practiced on Day 1. In one condition, the words are learned using repeated spaced retrieval practice - retrieval trials are initially immediate, then occur after 3 intervening words. In the other condition, the words and video are presented without retrieval trials. This practice schedule is repeated the next day (Day 2).~Testing sessions: 5 minutes after the learning session on Day 2, the child is asked to recall each word in the context of a sentence twice with actors and objects viewed during learning and twice with new actors and objects. One week after Day 1, this recall test is completed again. At this time, the child's ability to generalize the verb to a new sentence frame will be assessed. Finally, the child will complete a recognition test: viewing pairs of video clips, the child will hear each novel verb and point to the video clip that depicts that action.
Study: NCT04331132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolvaptan 15 MG
Description: vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan 15 MG
Description: vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
Study: NCT05062720

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Local consolidative therapy
Description: Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies